Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of BMN 110 in MPS IVA
NCT01242111Phase 2Terminated
- Sponsor
- BioMarin Pharmaceutical
- Start
- Nov 2010
- Primary completion
- Jul 2014
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of elosulfase alfa in mucopolysaccharidosis type IVA, sponsored by BioMarin Pharmaceutical. Started Nov 2010; status: terminated.
02
Drugs
elosulfase alfa
03
Conditions
mucopolysaccharidosis type IVA
Beyond the preview
Go deeper on NCT01242111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01242111.